The frequent presence of these ER-negative CTCs in patients with an ER-positive status in the primary tumour indicated a switch of ER phenotype or selection of minor ER-negative clones as a potential mechanism of escape from ER-targeting therapy [40]. The gene discussed is ESR1; the disease is neoplasm.